SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

AbbVie Wins Analyst Confidence With Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
Benzinga14:54 ET
10 Health Care Stocks Whale Activity In Today's Session
Benzinga13:35 ET
Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $200 Price Target
Benzinga13:24 ET · Ratings
Incyte Analyst Ratings
Benzinga12:58 ET · Ratings
Geneoscopy, Exact Sciences Case Over Cologuard to Be Heard by USPTO Board
Seeking Alpha12:00 ET
AbbVie Exits Alzheimer's Program on Lack of Differentiation
Seeking AlphaJul 26 11:18 ET

Comments

Moomoo News AU

Jul 10 04:25

Columns Australia's H2 2024 investment landscape: how to seize market opportunities?

Jinta Hong, CFA
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU)$ index reached a historic peak in April ...

+7

2024 half-year recap: Tell us your trading story

82

7

Fake BNF

Jun 25 08:42

$Ginkgo Bioworks(DNA.US)$ smth happened to this... 0.1 soon
It does not follow the XBI and Russell 2000 up trend for this period of time. Meaning market drops, it drops. Market ups, it still drop. Gonna cut off from my side

5

Shaaaw

Jun 25 07:07

Here’s why I think that $MRK buys $JANX soon.

$Merck & Co(MRK.US)$ on the prowl for acquisitions up to $15 billion.
$Merck & Co(MRK.US)$ already has an active partnership with $Janux Therapeutics(JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US)$ in which $Merck & Co(MRK.US)$ already has a seat at the table.
$Merck & Co(MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...

+1

9

Kopikarp

Jun 20 10:08

Bristol-Myers Squibb (BMY) - Options Strategy

Background and Recent Performance
$Bristol-Myers Squibb(BMY.US)$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US)$
Despite recent performance s...

TA Challenge: Are you a left-side or right-side trader?

15

Shaaaw

May 13 03:31

Short Interest of Life Sciences Companies at a High Point.
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US)$ $SPDR S&P Biotech ETF(XBI.US)$ $S&P 500 Index(.SPX.US)$

3

XBI SPDR S&P Biotech ETF

Trade Overview

Capital Trend

News

Comments